Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Vascepa to Accelerate Lipoprotein Uptake and Elimination (VALUE): An Open-Label, Mechanistic, Randomized, Controlled, Single-Center Trial of AMR101 in Patients With Dyslipidemia

NCT03885661 is registered in ClinicalTrials.gov with University of Pennsylvania as lead sponsor.

NCT NCT03885661
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03885661 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Vascepa to Accelerate Lipoprotein Uptake and Elimination (VALUE): An Open-Label, Mechanistic, Randomized, Controlled, Single-Center Trial of AMR101 in Patients With Dyslipidemia
Lead sponsor
University of Pennsylvania
Phase
Phase 1
Overall status
Completed
Start date
January 11, 2016
Completion date
June 30, 2021
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

dyslipidemias, lipid disorder, triglycerides high